P1.12B.07 Iruplinalkib in Patients with ALK-Positive Crizotinib-Resistant NSCLC: Updated Efficacy and Safety Data from a Phase 2 TrialYulong Shi, Xi Kang, Hui Zhang et al.|Journal of Thoracic Oncology|2024Cited by 0